Larimar Therapeutics Files 8-K
Ticker: LRMR · Form: 8-K · Filed: May 5, 2025 · CIK: 1374690
| Field | Detail |
|---|---|
| Company | Larimar Therapeutics, Inc. (LRMR) |
| Form Type | 8-K |
| Filed Date | May 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
TL;DR
Larimar Therapeutics filed an 8-K on 5/5/25, mostly procedural stuff.
AI Summary
On May 5, 2025, Larimar Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, formerly known as Zafgen, Inc., is incorporated in Delaware and headquartered in Bala Cynwyd, Pennsylvania.
Why It Matters
This 8-K filing indicates Larimar Therapeutics is providing updates or submitting required documentation to the SEC, which could contain important operational or financial information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific material events or financial disclosures that would indicate a high-risk situation.
Key Numbers
- 001-36510 — SEC File Number (Identifies the company's filing with the SEC)
- 20-3857670 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Larimar Therapeutics, Inc. (company) — Registrant
- ZAFGEN, INC. (company) — Former company name
- May 05, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Bala Cynwyd, Pennsylvania (location) — Principal executive offices
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The provided text only lists 'Other Events' as an item information category and does not specify the nature of these events.
Are there any new financial statements or exhibits included with this filing?
The filing indicates 'Financial Statements and Exhibits' as an item information category, but the content of these is not detailed in the provided text.
When was Larimar Therapeutics, Inc. formerly known as Zafgen, Inc.?
The filing indicates a former company name of ZAFGEN, INC. with a date of name change in 20100301 and ZAFGEN INC with a date of name change in 20060906.
What is the principal business address of Larimar Therapeutics, Inc.?
The principal executive offices are located at Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania, 19004.
What is the company's telephone number?
The company's telephone number, including area code, is (844) 511-9056.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 5, 2025 regarding Larimar Therapeutics, Inc. (LRMR).